Amphotericin B liposomal - Gilead Sciences

Drug Profile

Amphotericin B liposomal - Gilead Sciences

Alternative Names: AmBisome; SM 26000; SM-26000 Injection; SMP 26000

Latest Information Update: 14 Feb 2017

Price : $50

At a glance

  • Originator Gilead Sciences
  • Developer Gilead Sciences; Sumitomo Dainippon Pharma
  • Class Antifungals; Macrolides
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cryptococcosis; Febrile neutropenia; Fever of unknown origin; Mycoses; Visceral leishmaniasis
  • Preclinical Candidiasis
  • Discontinued Histoplasmosis

Most Recent Events

  • 27 Sep 2016 Gilead Science and World Health Organisation collaborate for expanded access of liposomal formulation of amphotericin B to diagnostic services and treatment for visceral leishmaniasis
  • 01 Jan 2015 Gilead completes a phase III trial in Mycoses (Prevention) in United Kingdom (NCT01259713)
  • 06 Oct 2014 AfriCoLeish under the sponsorship from the Drugs for Neglected Diseases initiative (DNDi) initiates enrolment in a phase III trial for the treatment of Visceral Leishmaniasis (HIV-infected patients) in Ethiopia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top